Skip to main content
Premium Trial:

Request an Annual Quote

GenMark, ALL Ink Definitive Agreement for IVD Platform Development

NEW YORK (GenomeWeb News) – GenMark Diagnostics and Advanced Liquid Logic today said they have executed definitive agreements to co-develop an all-digital, fully integrated in vitro diagnostic platform combining ALL's electrowetting technology and GenMark's electrochemical detection.

Today's agreement follows a preliminary deal announced by the firms earlier this year to develop the diagnostics platform. As part of the deal, Carlsbad, Calif.-based GenMark will pay ALL up to $3 million in license fees, contingent milestone payments, and an equity investment.

ALL, based in Durham, NC, develops microfluidics products for newborn screening and genomic sample preparation.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.